In a pivotal discussion during the January 2025 Board Meeting in Mississippi, a healthcare provider shared their experiences with COVID-19 treatments, highlighting the challenges faced during the pandemic. The provider revealed that they utilized non-FDA approved medications, such as hydroxychloroquine and remdesivir under Emergency Use Authorization (EUA), amid rising mortality rates and personal health concerns.

As the pandemic progressed, the demand for telemedicine consultations surged, prompting the provider to adapt their services. They began facilitating COVID-19 testing through mail orders, focusing on delivering timely care to patients in need. The provider emphasized their commitment to reviewing research publications to explore potential treatments, primarily using repurposed medications that had already established safety profiles with the FDA.

This discussion underscores the ongoing evolution of healthcare practices in response to the pandemic, reflecting both the urgency of patient needs and the complexities of treatment options available during unprecedented times. The insights shared during the meeting may influence future healthcare policies and practices as the board continues to navigate the implications of COVID-19 on public health.